Literature DB >> 28439341

Secukinumab: Review of Clinical Evidence from the Pivotal Studies ERASURE, FIXTURE, and CLEAR.

April W Armstrong1, Kim Papp2, Leon Kircik3.   

Abstract

Year:  2016        PMID： 28439341      PMCID： PMC5395241     

Source DB:  PubMed          Journal:  J Clin Aesthet Dermatol        ISSN： 1941-2789


× No keyword cloud information.
  10 in total

1.  Increased expression of interleukin-17 pathway genes in nonlesional skin of moderate-to-severe psoriasis vulgaris.

Authors:  A Chiricozzi; M Suárez-Fariñas; J Fuentes-Duculan; I Cueto; K Li; S Tian; C Brodmerkel; J G Krueger
Journal:  Br J Dermatol       Date:  2015-11-11       Impact factor: 9.302

2.  IL-17 induces inflammation-associated gene products in blood monocytes, and treatment with ixekizumab reduces their expression in psoriasis patient blood.

Authors:  Claire Q F Wang; Mayte Suárez-Fariñas; Kristine E Nograles; Claudia A Mimoso; David Shrom; Ernst R Dow; Michael P Heffernan; Robert W Hoffman; James G Krueger
Journal:  J Invest Dermatol       Date:  2014-07-07       Impact factor: 8.551

3.  Psoriasis prevalence among adults in the United States.

Authors:  Tara D Rachakonda; Clayton W Schupp; April W Armstrong
Journal:  J Am Acad Dermatol       Date:  2014-01-02       Impact factor: 11.527

4.  Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial.

Authors:  Diamant Thaçi; Andrew Blauvelt; Kristian Reich; Tsen-Fang Tsai; Francisco Vanaclocha; Külli Kingo; Michael Ziv; Andreas Pinter; Sophie Hugot; Ruquan You; Marina Milutinovic
Journal:  J Am Acad Dermatol       Date:  2015-06-17       Impact factor: 11.527

5.  Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study.

Authors:  K A Papp; R G Langley; B Sigurgeirsson; M Abe; D R Baker; P Konno; S Haemmerle; H J Thurston; C Papavassilis; H B Richards
Journal:  Br J Dermatol       Date:  2013-01-18       Impact factor: 9.302

6.  Secukinumab in plaque psoriasis--results of two phase 3 trials.

Authors:  Richard G Langley; Boni E Elewski; Mark Lebwohl; Kristian Reich; Christopher E M Griffiths; Kim Papp; Lluís Puig; Hidemi Nakagawa; Lynda Spelman; Bárður Sigurgeirsson; Enrique Rivas; Tsen-Fang Tsai; Norman Wasel; Stephen Tyring; Thomas Salko; Isabelle Hampele; Marianne Notter; Alexander Karpov; Silvia Helou; Charis Papavassilis
Journal:  N Engl J Med       Date:  2014-07-09       Impact factor: 91.245

7.  Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase II regimen-finding study.

Authors:  P Rich; B Sigurgeirsson; D Thaci; J-P Ortonne; C Paul; R E Schopf; A Morita; K Roseau; E Harfst; A Guettner; M Machacek; C Papavassilis
Journal:  Br J Dermatol       Date:  2013-02       Impact factor: 9.302

8.  Suppression of molecular inflammatory pathways by Toll-like receptor 7, 8, and 9 antagonists in a model of IL-23-induced skin inflammation.

Authors:  Mayte Suárez-Fariñas; Robert Arbeit; Weiwen Jiang; Francesca S Ortenzio; Tim Sullivan; James G Krueger
Journal:  PLoS One       Date:  2013-12-27       Impact factor: 3.240

9.  Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial.

Authors:  Iain B McInnes; Joachim Sieper; Jürgen Braun; Paul Emery; Désirée van der Heijde; John D Isaacs; Georg Dahmen; Jürgen Wollenhaupt; Hendrik Schulze-Koops; Joseph Kogan; Shenglin Ma; Martin M Schumacher; Arthur P Bertolino; Wolfgang Hueber; Paul P Tak
Journal:  Ann Rheum Dis       Date:  2013-01-29       Impact factor: 19.103

10.  Molecular Phenotyping Small (Asian) versus Large (Western) Plaque Psoriasis Shows Common Activation of IL-17 Pathway Genes but Different Regulatory Gene Sets.

Authors:  Jaehwan Kim; Chil-Hwan Oh; Jiehyun Jeon; Yoosang Baek; Jaewoo Ahn; Dong Joo Kim; Hyun-Soo Lee; Joel Correa da Rosa; Mayte Suárez-Fariñas; Michelle A Lowes; James G Krueger
Journal:  J Invest Dermatol       Date:  2016-01       Impact factor: 8.551
  10 in total
  2 in total

1.  Evaluation of the efficacy, safety, and side effects of secukinumab in patients with moderate-to-severe psoriasis: real-world data from a retrospective multicenter study.

Authors:  Ilteris Oguz Topal; Sevim Baysak; İlknur Kıvanç Altunay; Asude Kara Polat; Eylem Emel Arıkan; Ezgi Özkur; Sema Aytekin; Bilal Dogan; Tuğba Özkök Akbulut; Filiz Topaloğlu Demir; Ayşe Serap Karadağ
Journal:  An Bras Dermatol       Date:  2022-07-15       Impact factor: 2.113

2.  Safety and effectiveness of secukinumab in psoriasis vulgaris and psoriatic arthritis: Real-world evidence in Japan.

Authors:  Hideki Fujita; Mamitaro Ohtsuki; Akimichi Morita; Ryuji Nagao; Noriko Seko; Kazuko Matsumoto; Yumiko Tani; Tadashi Terui
Journal:  J Dermatol       Date:  2020-10-25       Impact factor: 4.005
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.